These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 35085819)

  • 1. Improvement in eosinophilic esophagitis when using dupilumab for other indications or compassionate use.
    Spergel BL; Ruffner MA; Godwin BC; Liacouras CA; Cianferoni A; Gober L; Hill DA; Brown-Whitehorn TF; Chaiboonma K; Aceves SA; Muir AM; Spergel JM
    Ann Allergy Asthma Immunol; 2022 May; 128(5):589-593. PubMed ID: 35085819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis.
    Wechsler ME; Klion AD; Paggiaro P; Nair P; Staumont-Salle D; Radwan A; Johnson RR; Kapoor U; Khokhar FA; Daizadeh N; Chen Z; Laws E; Ortiz B; Jacob-Nara JA; Mannent LP; Rowe PJ; Deniz Y
    J Allergy Clin Immunol Pract; 2022 Oct; 10(10):2695-2709. PubMed ID: 35636689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conjunctivitis in dupilumab clinical trials.
    Akinlade B; Guttman-Yassky E; de Bruin-Weller M; Simpson EL; Blauvelt A; Cork MJ; Prens E; Asbell P; Akpek E; Corren J; Bachert C; Hirano I; Weyne J; Korotzer A; Chen Z; Hultsch T; Zhu X; Davis JD; Mannent L; Hamilton JD; Teper A; Staudinger H; Rizova E; Pirozzi G; Graham NMH; Shumel B; Ardeleanu M; Wollenberg A
    Br J Dermatol; 2019 Sep; 181(3):459-473. PubMed ID: 30851191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained clinical and histopathological remission in a patient with eosinophilic esophagitis and type-2 comorbidities at 18 months after discontinuation of dupilumab.
    González-Uribe V; Rodríguez-Bueno CPA; Mojica-González ZS; Malagón-Liceaga A; Basile-Alvarez MR
    Clin J Gastroenterol; 2024 Oct; 17(5):803-808. PubMed ID: 39046661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global influence of dupilumab on Quality of Life in a severe asthma patient with T2 multimorbidities: a case report on atopic dermatitis, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis.
    Colque-Bayona M; Hernández-Cano N; Tomás-Pérez M; Caballero T; Quirce S; Domínguez-Ortega J
    J Asthma; 2024 Jul; 61(7):762-765. PubMed ID: 38152869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases.
    Hamilton JD; Harel S; Swanson BN; Brian W; Chen Z; Rice MS; Amin N; Ardeleanu M; Radin A; Shumel B; Ruddy M; Patel N; Pirozzi G; Mannent L; Graham NMH
    Clin Exp Allergy; 2021 Jul; 51(7):915-931. PubMed ID: 34037993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Efficacy of Dupilumab in Severe, Treatment-Refractory, and Fibrostenotic Patients With Eosinophilic Esophagitis.
    Lee CJ; Dellon ES
    Clin Gastroenterol Hepatol; 2024 Feb; 22(2):252-258. PubMed ID: 37660770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis.
    Hirano I; Dellon ES; Hamilton JD; Collins MH; Peterson K; Chehade M; Schoepfer AM; Safroneeva E; Rothenberg ME; Falk GW; Assouline-Dayan Y; Zhao Q; Chen Z; Swanson BN; Pirozzi G; Mannent L; Graham NMH; Akinlade B; Stahl N; Yancopoulos GD; Radin A
    Gastroenterology; 2020 Jan; 158(1):111-122.e10. PubMed ID: 31593702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relapse of Eosinophilic Esophagitis on Dupilumab.
    Buendia MA; Choksi YA; Hiremath G
    JPGN Rep; 2022 Nov; 3(4):e273. PubMed ID: 37168482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eosinophilic Esophagitis: Clinical Pearls for Primary Care Providers and Gastroenterologists.
    Goyal R; Kamboj AK; Snyder DL
    Mayo Clin Proc; 2024 Apr; 99(4):640-648. PubMed ID: 38569813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real World Experience With Dupilumab in Eosinophilic Esophagitis in Children and Young Adults at a Tertiary Care Pediatric Medical Center.
    Syverson EP; Rubinstein E
    JPGN Rep; 2022 May; 3(2):e180. PubMed ID: 37168913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of dupilumab in the treatment of eosinophilic esophagitis.
    Syverson EP; Rubinstein E; Lee JJ; McDonald DR; Hait E
    Immunotherapy; 2024; 16(13):845-852. PubMed ID: 39073081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age.
    Chehade M; Dellon ES; Spergel JM; Collins MH; Rothenberg ME; Pesek RD; Hirano I; Liu R; Laws E; Mortensen E; Martincova R; Shabbir A; McCann E; Kamal MA; Kosloski MP; Hamilton JD; Samuely C; Lim WK; Wipperman MF; Farrell A; Patel N; Yancopoulos GD; Glotfelty L; Maloney J
    N Engl J Med; 2024 Jun; 390(24):2239-2251. PubMed ID: 38924731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dupilumab ocular side effects in patients with atopic dermatitis: a systematic review.
    Neagu N; Dianzani C; Avallone G; Dell'Aquila C; Morariu SH; Zalaudek I; Conforti C
    J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):820-835. PubMed ID: 35122335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Evaluation of the Child with Eosinophilic Esophagitis.
    Bauer M; Nguyen N; Liacouras CA
    Immunol Allergy Clin North Am; 2024 May; 44(2):157-171. PubMed ID: 38575215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dupilumab in adolescent eosinophilic esophagitis: Experience with fibrostenosis and eosinophilic gastrointestinal disease with esophageal involvement.
    Becker R; Rigsby M; Suchi M; Lerner DG; Chugh A
    J Pediatr Gastroenterol Nutr; 2024 Jun; 78(6):1337-1341. PubMed ID: 38587127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of dupilumab-associated ocular surface diseases in atopic dermatitis patients.
    Guex-Crosier Y; Di-Lucca J; Häusermann P; Laffitte E; Saulite I; Schmid-Grendelmeier P; Schürch K; Thormann K; Simon D
    Swiss Med Wkly; 2021 Aug; 151():w30020. PubMed ID: 34495603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dupilumab: Mechanism of action, clinical, and translational science.
    McCann MR; Kosloski MP; Xu C; Davis JD; Kamal MA
    Clin Transl Sci; 2024 Aug; 17(8):e13899. PubMed ID: 39080841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One Year Into Dupilumab: Physician and Patient Experiences in Initiating Dupilumab for Pediatric Eosinophilic Esophagitis.
    Nguyen N; Burger C; Skirka S; White S; Smith M; Menard-Katcher C; Furuta GT; Mehta P
    J Pediatr Gastroenterol Nutr; 2023 Oct; 77(4):536-539. PubMed ID: 37491718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dupilumab Can Induce Remission of Eosinophilic Gastritis and Duodenitis: A Retrospective Case Series.
    Sia T; Bacchus L; Tanaka R; Khuda R; Mallik S; Leung J
    Clin Transl Gastroenterol; 2024 Jan; 15(1):e00646. PubMed ID: 37753954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.